SCHEMBL31470552

SCHEMBL31470552

COC(=O)c1cc(N)c(F)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.50
ALDH1A1 P00352 7/20 0.50
GAA P10253 6/20 0.50
MAPT P10636 4/20 0.50
HPGD P15428 4/20 0.50
HSD17B10 Q99714 3/20 0.50
GLA P06280 2/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
CFTR P13569 3/20 0.46
ABL1 P00519 1/20 0.45
TSHR P16473 2/20 0.44
ALOX15 P16050 1/20 0.44
POLB P06746 1/20 0.40
PDGFRB P09619 1/20 0.39
FGFR1 P11362 1/20 0.39
PDGFRA P16234 1/20 0.39
FLT1 P17948 1/20 0.39
FGFR3 P22607 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38663775 1.00 KDM4E (0.50) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL24821258 0.93 KDM4E (0.50) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL12164839 0.86 KDM4E (0.47) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL30221910 0.85 KDM4E (0.50) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL3529864 0.85 KDM4E (0.50) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL27890 0.85 KDM4E (0.43) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL1720999 0.85 KDM4E (0.56) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL20470613 0.83 PDGFRB (0.42) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL30280995 0.83 KDM4E (0.55) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL2897750 0.83 KDM4E (0.61) KDM4EALDH1A1GAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070287-A IRAK 4-targeted degradation agent compound and application thereof 江苏先声药业有限公司 2026-05-19 CN disclosed
US-12384773-B2 Thiazole compounds and methods of use thereof ARCUS BIOSCIENCES, INC. (US) 2025-08-12 US disclosed
WO-2025096979-A1 THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-05-08 WO disclosed
US-20250145606-A1 THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-05-08 US disclosed
WO-2025077891-A1 DEGRADATION AGENT COMPOUND TARGETING IRAK4, AND USE THEREOF 江苏先声药业有限公司 2025-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384773-B2 Thiazole compounds and methods of use thereof TPMT, CYP11B2, ABAT KDM4E 4753/4885ALDH1A1 198/4885GAA 158/4885
US-20250145606-A1 THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF TPMT, CYP11B2, ABAT KDM4E 4753/4885ALDH1A1 198/4885GAA 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.